Overall Score

Revenue Model

The company appears to monetize a single-product pharmaceutical model with very high gross margin (98.1%) but low revenue per share ($0.19 TTM), indicating limited current scale.

Price-to-sales remains elevated at 12.8x, suggesting the market is still pricing in future commercialization rather than current revenue strength.

Profitability

TTM margins remain deeply negative, with operating margin at -8.0% and net profit margin at -7.6%, showing the business is not yet profitable.

Return on equity (-64.7%) and return on invested capital (-57.7%) remain materially negative, reflecting weak capital efficiency.

Balance Sheet

Liquidity remains strong with a current ratio of 11.5x and cash ratio of 2.4x, supported by cash per share of $2.83 versus book value per share of $2.65.

The company carries no debt on the latest TTM metrics, reducing near-term solvency risk.

Cash Flow

Operating cash flow and free cash flow remain negative on a TTM basis, with free cash flow per share at -$1.36 and free cash flow yield at -55.6%.

Cash conversion remains poor despite a high gross margin, indicating the business is still consuming cash rather than generating it.

Growth Outlook

The model still depends on future product uptake rather than current growth, as revenue remains minimal relative to valuation.

No fresh news or updated guidance was provided this month to change the growth outlook.